• Ovid Therapeutics Inc OVID.OQ OVID.O is expected to show a rise in quarterly revenue when it reports results on March 6 (estimated) for the period ending December 31 2024

• The New York City-based company is expected to report a 33.3% increase in revenue to $189.29 thousand from $142 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Ovid Therapeutics Inc is for a loss of 17 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.50​, above​ its last closing price of $0.49. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated March 4 at 14:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)